Recombinant activated factor VII in clinical practice: a 2014 update

Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital hemophilia and inhibitors. Due to the initial success in this clinical setting, its use has been extended to other coagulopathies characterized by impaired thrombin generation, i....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and thrombolysis Jg. 39; H. 2; S. 235 - 240
Hauptverfasser:	Franchini, Massimo, Crestani, Silvia, Frattini, Francesco, Sissa, Cinzia, Bonfanti, Carlo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Boston Springer US 01.02.2015 Springer Nature B.V
Schlagworte:	Blood Coagulation - drug effects Cardiology Clinical Trials as Topic Factor VII Deficiency - drug therapy Factor VIIa - pharmacology Hematology Hemophilia A - drug therapy Hemostatics - pharmacology Humans Medicine Medicine & Public Health Recombinant Proteins - pharmacology Thrombasthenia - drug therapy FVII deficiency Recombinant activated FVII rFVIIa NovoSeven Hemophilia Acquired FVIII inhibitors Glanzmann’s thrombasthenia
ISSN:	0929-5305, 1573-742X, 1573-742X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!